A Food and Drug Administration (FDA) advisory committee convened March 8-9, 2011, to “discuss and make recommendations on scientific issues concerning direct to consumer (DTC) genetic tests that make medical claims.” Among other matters, the panel of experts is considering (i) “risks and benefits of making clinical genetic tests available for direct access by a consumer without the involvement of a clinician,” (ii) “risks and possible mitigations for incorrect, miscommunicated, or misunderstood test results,” and (iii) what “level and type of scientific evidence [is] appropriate for supporting direct-toconsumer genetic testing claims.” Among test categories already proposed to be offered to consumers are genetic carrier screening for hereditary diseases, tests to predict for the future development of disease in currently healthy individuals and tests for “treatment response prediction.”